|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1997-9-10
|
|
pubmed:abstractText |
Brimonidine is a highly selective alpha2-adrenoceptor agonist. It has intraocular pressure (IOP)-lowering characteristics similar to other alpha2-agonists and acts by reducing aqueous humor production and increasing uveoscleral outflow. It is oxidatively stable, which may account for its lower reported rate of ocular allergy compared with other alpha2-agonists. The focus of this report is to review the receptor pharmacology and clinical experience with brimonidine tartrate, the newest of the alpha2-adrenergic agonists.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1057-0829
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
250-8
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9264305-Adrenergic alpha-Agonists,
pubmed-meshheading:9264305-Adrenergic beta-Antagonists,
pubmed-meshheading:9264305-Betaxolol,
pubmed-meshheading:9264305-Clinical Trials as Topic,
pubmed-meshheading:9264305-Dose-Response Relationship, Drug,
pubmed-meshheading:9264305-Glaucoma,
pubmed-meshheading:9264305-Humans,
pubmed-meshheading:9264305-Intraocular Pressure,
pubmed-meshheading:9264305-Ocular Hypertension,
pubmed-meshheading:9264305-Ophthalmic Solutions,
pubmed-meshheading:9264305-Quinoxalines,
pubmed-meshheading:9264305-Timolol,
pubmed-meshheading:9264305-Trabeculectomy
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
|
|
pubmed:affiliation |
Department of Ophthalmology, New York Eye and Ear Infirmary, New York 10003, U.S.A.
|
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|
